CatalYm GmbH GDFATHER (Metastatic Non-Squamous Non-Small Cell Lung Cancer) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find the most effective, safe dose of an experimental drug called visugromab (CTL-002 - the study drug). We want to find out how beneficial this drug is when it is used in combination with immunochemotherapy for people with metastatic non-squamous non-small cell lung cancer.
Metastatic Non-Squamous Non-Small Cell Lung Cancer
Who Can Participate in the Study?
Adults ages 18+ who:
- Are newly diagnosed with stage IV non-squamous NSCLC
- Have not received prior systemic treatment for advanced/metastatic NSCLC
For more information, contact the study team at annemarie.peters@duke.edu.
What is Involved?
If you choose to join this study, you will start with the safety run-in portion of this study. During this part, different doses of the study drug will be tested to determine which dose will be given during the randomized part.
When you proceed to the randomized part of the study, you will get a random assignment (by chance) to either take the study drug or a placebo (inactive substance that has no drug in it). You will have a 2-in-3 chance of getting the study drug.
Regardless of whether or not you are assigned to get the study drug, you will still receive the standard immunochemotherapy that is used to treat this diagnosis. The study drug/placebo regimen in this study will last for up to 2 years.
Study Details
